MGC Pharmaceuticals Limited’s () () Roby Zomer talks to Proactive London about receiving Ethics Committee approvals from the Rambam Health Care Campus and the Nazareth Hospital EMMS in Israel for Phase III clinical trials of its CimetrA treatment.
Zomer explains that these patients are above 18 years of age with a history of illnesses which can be diabetics, heart or lung diseases and classified by FDA as a ‘high classified group’ and already hospitalised with symptoms of Coronavirus (COVID-19).
Read More: MGC Pharmaceuticals wins approval for Phase III trial of CimetrA ‘giving more